» Articles » PMID: 27535376

Resveratrol Defends Blood-brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis Mice

Overview
Journal J Neurophysiol
Specialties Neurology
Physiology
Date 2016 Aug 19
PMID 27535376
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The mouse autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS), is primarily characterized as dysfunction of the blood-brain barrier (BBB). Resveratrol exhibits anti-inflammatory, antioxidative, and neuroprotective activities. We investigated the beneficial effects of resveratrol in protecting the integrity of the BBB in EAE mice and observed improved clinical outcome in the EAE mice after resveratrol treatment. Evans blue (EB) extravasation was used to detect the disruption of BBB. Western blot were used to detected the tight junction proteins and adhesion molecules zonula occludens-1 (ZO-1), occludin, ICAM-1, and VCAM-1. Inflammatory factors inducible nitric oxide synthase (iNOS), IL-1β, and arginase 1 were evaluated by quantitative RT-PCR (qPCR) and IL-10 by ELISA. NADPH oxidase (NOX) levels were evaluated by qPCR, and its activity was analyzed by lucigenin-derived chemiluminescence. Resveratrol at doses of 25 and 50 mg/kg produced a dose-dependent decrease in EAE paralysis and EB leakage, ameliorated EAE-induced loss of tight junction proteins ZO-1, occludin, and claudin-5, as well as repressed the EAE-induced increase in adhesion proteins ICAM-1 and VCAM-1. In addition, resveratrol suppressed the EAE-induced overexpression of proinflammatory transcripts iNOS and IL-1β and upregulated the expression of anti-inflammatory transcripts arginase 1 and IL-10 cytokine in the brain. Furthermore, resveratrol downregulated the overexpressed NOX2 and NOX4 in the brain and suppressed NADPH activity. Resveratrol ameliorates the clinical severity of MS through maintaining the BBB integrity in EAE mice.

Citing Articles

A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE).

Martorelli M, Dengler M, Laux J, Fischer T, Vaiceliunaite A, Hahn U ACS Pharmacol Transl Sci. 2024; 7(12):3827-3845.

PMID: 39698286 PMC: 11650733. DOI: 10.1021/acsptsci.4c00189.


Role of Plant Phytochemicals: Resveratrol, Curcumin, Luteolin and Quercetin in Demyelination, Neurodegeneration, and Epilepsy.

Grabarczyk M, Justynska W, Czpakowska J, Smolinska E, Bielenin A, Glabinski A Antioxidants (Basel). 2024; 13(11).

PMID: 39594506 PMC: 11591432. DOI: 10.3390/antiox13111364.


Antioxidant Therapies in the Treatment of Multiple Sclerosis.

Jimenez-Jimenez F, Alonso-Navarro H, Salgado-Camara P, Garcia-Martin E, Agundez J Biomolecules. 2024; 14(10).

PMID: 39456199 PMC: 11506420. DOI: 10.3390/biom14101266.


Intranasal Resveratrol Nanoparticles Enhance Neuroprotection in a Model of Multiple Sclerosis.

Shamsher E, Khan R, Davis B, Dine K, Luong V, Cordeiro M Int J Mol Sci. 2024; 25(7).

PMID: 38612856 PMC: 11012060. DOI: 10.3390/ijms25074047.


Effects of topical application of resveratrol on tight junction barrier and antimicrobial compound production in lactating goat mammary glands.

Tsugami Y, Nii T, Isobe N Vet Res. 2024; 55(1):20.

PMID: 38365712 PMC: 10870570. DOI: 10.1186/s13567-024-01276-z.


References
1.
Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan R, Dine K, Dutt M . Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol. 2012; 3:84. PMC: 3359579. DOI: 10.3389/fneur.2012.00084. View

2.
Zhang F, Liu J, Shi J . Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol. 2010; 636(1-3):1-7. DOI: 10.1016/j.ejphar.2010.03.043. View

3.
Glenn J, Smith M, Calabresi P, Whartenby K . Mesenchymal stem cells differentially modulate effector CD8+ T cell subsets and exacerbate experimental autoimmune encephalomyelitis. Stem Cells. 2014; 32(10):2744-55. PMC: 7568282. DOI: 10.1002/stem.1755. View

4.
Vallejo S, Palacios E, Romacho T, Villalobos L, Peiro C, Sanchez-Ferrer C . The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2014; 13:158. PMC: 4276125. DOI: 10.1186/s12933-014-0158-z. View

5.
Yang X, Yan J, Feng J . Treatment with tanshinone IIA suppresses disruption of the blood-brain barrier and reduces expression of adhesion molecules and chemokines in experimental autoimmune encephalomyelitis. Eur J Pharmacol. 2015; 771:18-28. DOI: 10.1016/j.ejphar.2015.12.014. View